current partners

In April 2006, Pieris signed a research collaboration with GE Healthcare for the discovery of novel targeted in vivo diagnostic and medical imaging compounds based upon Anticalins®. The parties are developing novel agents for the early detection and diagnosis for diseases such as cancer. Pieris has retained all rights for therapeutic use.

In April 2005, Pieris entered into an agreement with Syngenta AG of Basel, Switzerland to develop an Anticalin® based therapeutic to treat asthma, a disease with high unmet medical need. In its first year the collaboration has made good progress and has met its pre-designated performance milestones. In December 2006, Pieris regained full control over this therapeutic after the partner abandoned all biotech activities.

In July 2003, Pieris formed a strategic alliance with the Technical University of Munich in order to broaden the company's technology base and secure further developments in the basic understanding of lipocalins and Anticalins®. Any patent rights arising are assigned to Pieris and the company has the exclusive right to in-license future inventions in the area of lipocalins and Anticalins®.